Zentiva Reveals Progress On Sitagliptin
Zent2U B2B Unit Also Celebrates Completion Of Sertraline Bioequivalence Study
Executive Summary
Zentiva’s Zent2U B2B unit has reported progress on a bioequivalence study for its sitagliptin tablets, indicating that its version will be ready for day-one entry in Europe. The development comes shortly after Zent2U announced the successful completion of a sertraline study.